A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

Exclusion Criteria

• •Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
• •Received radiation therapy to the lung
• •Has uncontrolled or significant cardiovascular disorder prior to randomization
• •Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
• •Participants who have adverse events (AEs) (other than alopecia) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline
• •Has known severe hypersensitivity (≥Grade 3) to study intervention and/or any of its excipients
• •Has clinically significant corneal disease
• •Has received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids
• •Has inadequate washout period prior to randomization
• •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
• •Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
• •Has previously received docetaxel as monotherapy or in combination with other therapies
• •Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
• •Has known additional malignancy that is progressing or has required active treatment within the past 3 years
• •Has known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
• •Has evidence of any leptomeningeal disease
• •Has history of interstitial lung disease (ILD)/pneumonitis, current diagnosis of ILD, and/or suspected ILD
• •Has active autoimmune disease that has required systemic treatment in the past 2 years
• •Has active infection requiring systemic therapy
• •HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
• •Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease
• •Has known history of, or active, neurologic paraneoplastic syndrome
• •Has history of allogeneic tissue/solid organ transplant
• •Have not adequately recovered from major surgery or have ongoing surgical complications